OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($1.08) per share for the quarter.
OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported ($1.37) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.51). On average, analysts expect OnKure Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
OnKure Therapeutics Stock Performance
Shares of OKUR stock traded up $0.05 during trading hours on Friday, reaching $5.05. 19,042 shares of the company's stock were exchanged, compared to its average volume of 85,453. The stock has a market cap of $67.85 million, a PE ratio of -0.41 and a beta of 0.28. The firm has a fifty day moving average price of $5.44. OnKure Therapeutics has a 1 year low of $4.45 and a 1 year high of $20.00.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on OKUR shares. Leerink Partners began coverage on shares of OnKure Therapeutics in a research note on Thursday, December 5th. They set an "outperform" rating and a $33.00 price target on the stock. Leerink Partnrs upgraded OnKure Therapeutics to a "strong-buy" rating in a research note on Thursday, December 5th. HC Wainwright dropped their price target on OnKure Therapeutics from $40.00 to $34.00 and set a "buy" rating on the stock in a research note on Tuesday, March 18th. Finally, Oppenheimer reduced their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an "outperform" rating for the company in a research note on Tuesday, March 11th. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $32.33.
View Our Latest Research Report on OnKure Therapeutics
About OnKure Therapeutics
(
Get Free Report)
OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.
Featured Articles
Before you consider OnKure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OnKure Therapeutics wasn't on the list.
While OnKure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
